Nisbet-Brown E. Olivieri NF. Giardina PJ. Grady RW. Neufeld EJ. Sechaud R. Krebs-Brown AJ. Anderson JR. Alberti D. Sizer KC. Nathan DG. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomized, double-blind, placebo-controlled, dose-escalation trial. Lancet. 361: 1597-1602, 2003 May 10.

Driscoll MC. Hurlet A. Styles L. McKie V. Files B. Olivieri N. Pegelow C. Berman B. Drachtman R. Patel K. Brambilla D. Stroke risk in siblings with sickle cell anemia. Blood. 101(6):2401-4, 2003 Mar 15.

Brittenham GM. Nathan DG. Olivieri NF. Pippard MJ. Weatherall DJ. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.[comment]. Lancet. 361(9352):183; author reply 183-4, 2003 Jan 11.

Olivieri NF. Patients' health or company profits? The commercialisation of academic research. Science & Engineering Ethics. 9(1):29-41, 2003 Jan.

Steinberg MH. Barton F. Castro O. Pegelow CH. Ballas SK. Kutlar A. Orringer E. Bellevue R. Olivieri N. Eckman J. Varma M. Ramirez G. Adler B. Smith W. Carlos T. Ataga K. DeCastro L. Bigelow C. Saunthararajah Y. Telfer M. Vichinsky E. Claster S. Shurin S. Bridges K. Waclawiw M. Bonds D. Terrin M. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment.[comment]. JAMA. 289(13):1645-51, 2003 Apr 2.

Vichinsky EP. Luban NL. Wright E. Olivieri N. Driscoll C. Pegelow CH. Adams RJ. Stroke Prevention Trail in Sickle Cell Anemia. Prospective RBC phenotype matching in a stroke-prevention trial in sickle cell anemia: a multicenter transfusion trial.[comment]. Transfusion. 41(9):1086-92, 2001 Sep.

Vichinsky EP. Luban NL. Wright E. Olivieri N. Driscoll C. Pegelow CH. Adams RJ. Stroke Prevention Trail in Sickle Cell Anemia. Prospective RBC phenotype matching in a stroke-prevention trial in sickle cell anemia: a multicenter transfusion trial. Transfusion. 41(9):1086-92, 2001 Sep.

Olivieri NF. Progression of iron overload in sickle cell disease. Seminars in Hematology. 38(1 Suppl 1):57-62, 2001 Jan.

Kushner JP. Porter JP. Olivieri NF. Secondary iron overload. [Review] [183 refs] Hematology. :47-61, 2001.

Olivieri NF. De Silva S. Premawardena A. Sharma S. Viens AM. Taylor CM. Brittenham GM. Weatherall DJ. Iron overload and iron-chelating therapy in hemoglobin E-beta thalassemia. Journal of Pediatric Hematology/Oncology. 22(6):593-7, 2000 Nov-Dec.

de Silva S. Fisher CA. Premawardhena A. Lamabadusuriya SP. Peto TE. Perera G. Old JM. Clegg JB. Olivieri NF. Weatherall DJ. Thalassaemia in Sri Lanka: implications for the future health burden of Asian populations. Sri Lanka Thalassaemia Study Group. Lancet. 355(9206):786-91, 2000 Mar 4.

Olivieri NF. The beta-thalassemias.[erratum appears in N Engl J Med 1999 Oct 28;341(18):1407]. [Review] [120 refs] New England Journal of Medicine. 341(2):99-109, 1999 Jul 8.

Olivieri N. Thalassaemia: clinical management. [Review] [116 refs] Baillieres Clinical Haematology. 11(1):147-62, 1998 Mar.

Olivieri NF. Rees DC. Ginder GD. Thein SL. Waye JS. Chang L. Brittenham GM. Weatherall DJ. Elimination of transfusions through induction of fetal hemoglobin synthesis in Cooley's anemia. Annals of the New York Academy of Sciences. 850:100-9, 1998 Jun 30.

Olivieri NF. Brittenham GM. Long-term trials of deferiprone in Cooley's anemia. [Review] [30 refs] Annals of the New York Academy of Sciences. 850:217-22, 1998 Jun 30.

Adams RJ. McKie VC. Brambilla D. Carl E. Gallagher D. Nichols FT. Roach S. Abboud M. Berman B. Driscoll C. Files B. Hsu L. Hurlet A. Miller S. Olivieri N. Pegelow C. Scher C. Vichinsky E. Wang W. Woods G. Kutlar A. Wright E. Hagner S. Tighe F. Waclawiw MA. et al. Stroke prevention trial in sickle cell anemia. Controlled Clinical Trials. 19(1):110-29, 1998 Feb.

Olivieri NF. Brittenham GM. McLaren CE. Templeton DM. Cameron RG. McClelland RA. Burt AD. Fleming KA. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major.[comment]. New England Journal of Medicine. 339(7):417-23, 1998 Aug 13.

Olivieri NF. Brittenham GM. Iron-chelating therapy and the treatment of thalassemia.[comment][erratum appears in Blood 1997 Apr 1;89(7):2621]. [Review] [314 refs] Blood. 89(3):739-61, 1997 Feb 1.

Olivieri NF. Fetal erythropoiesis and the diagnosis and treatment of hemoglobin disorders in the fetus and child. [Review] [53 refs] Seminars in Perinatology. 21(1):63-9, 1997 Feb.

Olivieri NF. Rees DC. Ginder GD. Thein SL. Brittenham GM. Waye JS. Weatherall DJ. Treatment of thalassaemia major with phenylbutyrate and hydroxyurea. Lancet. 350(9076):491-2, 1997 Aug 16.

Olivieri NF. Orally active iron chelators in the treatment of iron overload. [Review] [61 refs] Current Opinion in Hematology. 3(2):125-30, 1996 Mar.

Olivieri NF. Reactivation of fetal hemoglobin in patients with beta-thalassemia. [Review] [121 refs] Seminars in Hematology. 33(1):24-42, 1996 Jan.

Liu P. Henkelman M. Joshi J. Hardy P. Butany J. Iwanochko M. Clauberg M. Dhar M. Mai D. Waien S. Olivieri N. Quantification of cardiac and tissue iron by nuclear magnetic resonance relaxometry in a novel murine thalassemia-cardiac iron overload model. Canadian Journal of Cardiology. 12(2):155-64, 1996 Feb.

Olivieri NF. Long-term therapy with deferiprone. [Review] [90 refs] Acta Haematologica. 95(1):37-48, 1996.

al-Refaie FN. Hershko C. Hoffbrand AV. Kosaryan M. Olivieri NF. Tondury P. Wonke B. Results of long-term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron Chelators. British Journal of Haematology. 91(1):224-9, 1995 Sep.

Olivieri NF. Brittenham GM. Matsui D. Berkovitch M. Blendis LM. Cameron RG. McClelland RA. Liu PP. Templeton DM. Koren G. Iron-chelation therapy with oral deferipronein patients with thalassemia major.[comment]. New England Journal of Medicine. 332(14):918-22, 1995 Apr 6.

Olivieri NF. Nathan DG. MacMillan JH. Wayne AS. Liu PP. McGee A. Martin M. Koren G. Cohen AR. Survival in medically treated patients with homozygous beta-thalassemia.[comment]. New England Journal of Medicine. 331(9):574-8, 1994 Sep 1.

Liu P. Olivieri N. Iron overload cardiomyopathies: new insights into an old disease. [Review] [60 refs] Cardiovascular Drugs & Therapy. 8(1):101-10, 1994 Feb.

Olivieri NF. Liu PP. Sher GD. Daly PA. Greig PD. McCusker PJ. Collins AF. Francombe WH. Templeton DM. Butany J. Brief report: combined liver and heart transplantation for end-stage iron-induced organ failure in an adult with homozygous beta-thalassemia. New England Journal of Medicine. 330(16):1125-7, 1994 Apr 21.

Perrine SP. Ginder GD. Faller DV. Dover GH. Ikuta T. Witkowska HE. Cai SP. Vichinsky EP. Olivieri NF. A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders.[comment]. New England Journal of Medicine. 328(2):81-6, 1993 Jan 14.

Olivieri NF. Matsui D. Liu PP. Blendis L. Cameron R. McClelland RA. Templeton DM. Koren G. Oral iron chelation with 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron loaded thalassemia patients. Bone Marrow Transplantation. 12 Suppl 1:9-11, 1993.

Olivieri NF. Koren G. Harris J. Khattak S. Freedman MH. Templeton DM. Bailey JD. Reilly BJ. Growth failure and bony changes induced by deferoxamine. American Journal of Pediatric Hematology-Oncology. 14(1):48-56, 1992 Spring.

Olivieri NF. Koren G. Matsui D. Liu PP. Blendis L. Cameron R. McClelland RA. Templeton DM. Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia. Blood. 79(10):2741-8, 1992 May 15.

Bronspiegel-Weintrob N.Olivieri NF. Tyler B. Andrews DF. Freedman MH. Holland FJ. Effect of age at the start of iron chelation therapy on gonadal function in beta-thalassemia major. New England Journal of Medicine. 323(11):713-9, 1990 Sep 13.

Olivieri NF. Koren G. Hermann C. Bentur Y. Chung D. Klein J. St Louis P. Freedman MH. McClelland RA. Templeton DM. Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients. Lancet. 336(8726):1275-9, 1990 Nov 24.

Olivieri NF. Koren G. St Louis P. Freedman MH. McClelland RA. Templeton DM. Studies of the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one in thalassemia patients. Seminars in Hematology. 27(2):101-4, 1990 Apr.

Olivieri NF. Templeton DM. Koren G. Chung D. Hermann C. Freedman MH. McClelland RA. Evaluation of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients. Annals of the New York Academy of Sciences. 612:369-77, 1990.

Olivieri NF. Buncic JR. Chew E. Gallant T. Harrison RV. Keenan N. Logan W. Mitchell D. Ricci G. Skarf B. et al. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. New England Journal of Medicine. 314(14):869-73, 1986 Apr 3.

Wolfe L. Olivieri N. Sallan D. Colan S. Rose V. Propper R. Freedman MH. Nathan DG. Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. New England Journal of Medicine. 312(25):1600-3, 1985 Jun 20.